{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:53:42Z","timestamp":1790787222633,"version":"4.1.0"},"reference-count":9,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["SAGE Open Medical Case Reports"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p> Bullous pemphigoid is an acquired autoimmune subepidermal blistering disease that can arise following exposure to systemic medication, referred to as drug-induced bullous pemphigoid. Drug-induced bullous pemphigoid is a rare but potentially serious immune-related adverse event that should be considered in patients with advanced malignancies undergoing immunotherapy, with immune checkpoint inhibitors emerging in particular as a well-documented drug association in drug-induced bullous pemphigoid. We present a 74-year-old female with recurrent metastatic programmed cell death-ligand 1\u2013positive squamous cell carcinoma of the head and neck area who developed drug-induced bullous pemphigoid in the setting of immunotherapy with a novel immunoglobulin-like transcript 4 inhibitor (MK-4830) in combination with pembrolizumab. Treatment with upadacitinib, a Janus-associated kinase-1 inhibitor, was pursued for significantly disabling disease that was recalcitrant to standard therapies and ultimately transition to palliative care. Follow-up at 4\u2009weeks demonstrated good response. This is the first report describing the use of a Janus-associated kinase inhibitor for the treatment of bullous pemphigoid. <\/jats:p>","DOI":"10.1177\/2050313x231160926","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T06:30:35Z","timestamp":1679466635000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":21,"title":["A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8614-1776","authenticated-orcid":false,"given":"Louise M","family":"Gresham","sequence":"first","affiliation":[{"name":"Division of Dermatology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G","family":"Kirchhof","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"bibr1-2050313X231160926","doi-asserted-by":"publisher","DOI":"10.1177\/1203475420943260"},{"key":"bibr2-2050313X231160926","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220946370"},{"key":"bibr3-2050313X231160926","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13984"},{"key":"bibr4-2050313X231160926","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3740"},{"key":"bibr5-2050313X231160926","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.068"},{"key":"bibr6-2050313X231160926","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6716419"},{"key":"bibr7-2050313X231160926","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108923"},{"key":"bibr8-2050313X231160926","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0029"},{"key":"bibr9-2050313X231160926","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002012"}],"container-title":["SAGE Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X231160926","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X231160926","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X231160926","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T04:46:37Z","timestamp":1740890797000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X231160926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":9,"alternative-id":["10.1177\/2050313X231160926"],"URL":"https:\/\/doi.org\/10.1177\/2050313x231160926","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"value":"2050-313X","type":"print"},{"value":"2050-313X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"2050313X231160926"}}